The tyrosine kinase inhibitor cabozantinib has shown promising activity against brain metastases in patients with renal cell carcinoma (RCC), achieving a 50% response rate, according to US researchers. A retrospective cohort study involving 88 patients with metastatic RCC and brain metastases treated in 15 international institutions showed that cabozantinib could potentially pass through the blood-brain ...
Cabozantinib shows promising effects on brain metastases in RCC
By Michael Woodhead
22 Oct 2021